Edward Mott
Chairman @ Oxford Capital
Oxford, United Kingdom
Edward Mott is a funding round investor at Oxford Capital in Oxford focused on Biotechnology and Medical. Edward co-founded Oxford Capital in 1999 with the intent of broadening the access to private equity to wealthy families and corporations around the world as well as to institutional investors. He chairs the Investment Committee at Oxford Capital. With over 30 years of experience as a business leader, practical manager, investor and companydirector, Ted has worked with both mature listed businesses and younger high growth companies across a multitude of sectors. He has also been actively involved in a wide range of infrastructure projects. Following an early career in the US with Corning Glass Inc. where he was involved with the first commercialisation of fibre optics, he then pursued a career in investment banking with American, European and Asian banks in corporate finance, emerging markets and structured finance, before heading HSBC’s capital markets division based in Hong Kong. He later served the wealth manager GAM in London with responsibility for both institutional and private clients before founding Oxford Capital. Ted is a graduate of the University of Cambridge and an INSEAD MBA and is fluent in French and German. Ted is also a keen sailor and gardener.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Edward Mott invests in
Stages Edward Mott invests in
Countries Edward Mott invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (27%)
- Medical 2 (13%)
- Chemical 2 (13%)
- Agriculture 2 (13%)
- Life Science 2 (13%)
Stage
- Funding Round 5 (33%)
- Venture - Series Unknown 2 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Microbial Solutions Limited offers a technology that can provide on-site treatment and disposal of MWFs which can unlock and release the replacement value of both the existing treatment technology and the associated logistics costs. The Microcycle™ technology is a powerful, patented biological degradation process that reduces waste MWFs toacceptable COD concentrations, removes toxicity and allows for the safe disposal of MWF as grey water to sewers on site. Through their offering, Microbial Solutions seeks to help their clients to cost-effectively meet their environmental responsibilities and to provide regulators with the tools to implement the regulations enshrining those responsibilities. | $770K / Venture - Series Unknown / Feb 13, 2015 | ||
| Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $2.4M / Venture - Series Unknown / Jan 16, 2015 | ||
| Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well asagricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests. | $10M / Jun 24, 2014 | ||
| Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $3.3M / May 28, 2013 | ||
| Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | Nov 02, 2012 | ||
| Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well asagricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests. | $10.5M / Feb 14, 2012 | ||
| Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $1.8M / Jan 18, 2012 | ||
| Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $1M / Oct 14, 2011 | ||
| Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well asagricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests. | $4.6M / Mar 29, 2011 | ||
| Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is oneof the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities. | $902K / Aug 20, 2010 | ||
| See all 15 investments → | |||
Co-Investors
About Oxford Capital
Oxford Capital is an experienced technology venture capital investor based in London and Oxford. They focus on investing in a diversified portfolio of high-potential pure technology and technology-enabled start-up businesses.
Oxford Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Edward Mott
Chairman
|
|||
Chris Payne
Investor
|
|||
David Mott
Founder Partner
|
|||
James Witter
Non-Executive Director
|
|||
Richard Roberts
Director, Investor Relations
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Edward Mott invest in?
Edward Mott invests primarily in Biotechnology, Medical and Chemical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 15 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Edward Mott?
Public channels for Edward Mott include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Edward Mott last invest?
The most recent investment recorded for Edward Mott closed in Feb 2015. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
